Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Therapeutic Morass.

Cardiology 2018 23;140(4):213-221. Epub 2018 Aug 23.

Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.

Valvular heart disease is a common pathologic condition that affects 6 million people in the United States and more than 100 million worldwide. The most common valvular disorder is aortic stenosis. Current American and European guidelines recommend surgical management for symptomatic aortic stenosis with low risk of perioperative complications and endovascular intervention for high-risk patients with multiple comorbidities. Considering the increasing volume of aortic valve replacement (AVR) with biological valves, it is very important to select the appropriate anticoagulant after surgical AVR. In this article, we review the impact of anticoagulation on immediate and remote complications after AVR.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490924DOI Listing
October 2019
34 Reads
2.044 Impact Factor

Publication Analysis

Top Keywords

aortic valve
8
valve replacement
8
aortic stenosis
8
risk perioperative
4
perioperative complications
4
complications endovascular
4
endovascular intervention
4
patients multiple
4
high-risk patients
4
intervention high-risk
4
low risk
4
symptomatic aortic
4
american european
4
current american
4
stenosis current
4
european guidelines
4
guidelines recommend
4
multiple comorbidities
4
management symptomatic
4
recommend surgical
4

Similar Publications